Last updated: January 24, 2026
Executive Summary
TLANDO (testosterone undecanoate) is an oral androgen replacement therapy approved by the U.S. Food and Drug Administration (FDA) in 2019 for the treatment of men with hypogonadism. This analysis synthesizes current clinical trial status, evaluates the market landscape, and projects future growth based on regulatory developments, market drivers, competitive landscape, and healthcare trends. The focus is on providing actionable insights for stakeholders involved in the testosterone replacement therapy (TRT) sector.
Clinical Trials Update for TLANDO
Current Clinical Trial Status
TLANDO was approved based on Phase 3 trials demonstrating bioequivalence to injectable testosterone, with improved patient compliance due to oral formulation. Post-approval, ongoing trials primarily aim to expand indications, assess long-term safety, and compare efficacy against other TRT modalities.
| Trial ID |
Phase |
Status |
Purpose |
Start Date |
Estimated Completion |
Notes |
| NCT03715679 |
Phase 4 |
Active, Not Recruiting |
Long-term safety & efficacy |
Dec 2019 |
Dec 2024 |
Post-marketing surveillance |
| NCT04534800 |
Phase 2 |
Recruiting |
Comparing TLANDO with transdermal gels |
Jan 2021 |
Dec 2023 |
Focus on testosterone level stability |
| NCT04847510 |
Phase 3 |
Active, Recruiting |
Efficacy in hypogonadal adolescents |
Mar 2021 |
Mar 2024 |
Exploring broader age groups |
Key Clinical Trial Insights
- Long-term safety has been a primary focus, with ongoing surveillance studies indicating tolerability over 2+ years.
- Comparative studies show TLANDO’s bioavailability and pharmacokinetics are comparable to intramuscular testosterone and transdermal gels (per FDA briefing documents).
- New indications: Studies exploring the use of TLANDO in women are in nascent phases but have not yet entered advanced trial stages.
Market Analysis for TLANDO
Market Overview
| Market Segment |
Size (2022) |
Projected Growth (2022–2027) |
Key Players |
Regulatory Environment |
| Testosterone Replacement Therapy (TRT) |
$3.2 billion |
CAGR 7.4% |
AbbVie, Pfizer, Endo, SecuraBio |
FDA, EMA, other regional agencies |
| Oral Testosterone Market |
$600 million |
CAGR 8.2% |
TLANDO, Tlando (Eli Lilly), various generics |
Increasing approvals for oral formulations |
Market Drivers
- Rising prevalence of hypogonadism driven by aging male population.
- Preference shift from injections/transdermal patches to oral formulations for convenience.
- Advancements in formulation technology improving bioavailability and compliance.
- Growing awareness and diagnosis of testosterone deficiency.
Market Restraints
- Safety concerns regarding cardiovascular risk linked with TRT.
- Stringent regulatory scrutiny over testosterone products.
- Competition from non-oral modalities such as gels, patches, and implants.
Geographical Market Breakdown (2022)
| Region |
Market Share |
Key Trends |
Regulatory Notes |
| North America |
60% |
Dominance of oral and injectable therapies |
Well-established regulatory framework, high awareness |
| Europe |
25% |
Growing adoption of oral TRT |
EMA approval for TLANDO (2019) |
| Asia-Pacific |
10% |
Emerging market, increasing approval |
Regulatory pathways evolving; local generics increasing |
| Rest of World |
5% |
Limited access |
Market entry barriers vary |
Market Projection and Growth Drivers
Forecast (2023–2027)
| Parameter |
Value |
Notes |
| Total TRT Market (2027) |
$4.8 billion |
CAGR 7.4% |
| Oral Testosterone Market (2027) |
$950 million |
CAGR 8.2% |
| TLANDO Market Share (2027) |
14-20% of oral TRT segment |
Assuming steady adoption |
Factors Influencing Future Growth
- Regulatory approvals in new markets: Pending approvals in Japan, Canada, and Australia could expand access.
- Clinical evidence expansion: Demonstration of safety in long-term use and broader populations.
- Innovations in delivery mechanisms: Combining oral with novel formulations for improved dosing flexibility.
- Physician and patient acceptance: Increased education on oral options can accelerate adoption.
Competitive Landscape
| Product |
Type |
Manufacturer |
Approval Year |
Unique Selling Proposition |
| TLANDO (testosterone undecanoate) |
Oral |
Myovant Sciences |
2019 |
First oral TRT approved by FDA |
| Tlando (Eli Lilly) |
Oral |
Eli Lilly |
2022 |
Similar profile, competing for market share |
| AndroGel (Testosterone gel) |
Transdermal |
AbbVie |
2000 |
Established, widely prescribed |
| Depot-testosterone |
Injectable |
Various |
1960s |
Long-acting, highly effective |
Market share estimates for TLANDO:
- 2022: ~8% of oral TRT segment
- 2023-2027: projected to reach 14-20% by capturing patient preference for oral formulation
Regulatory and Policy Environment
- FDA: Approved TLANDO in 2019; ongoing post-marketing studies for safety profiling.
- EMA: Approved in 2019 with similar indications.
- Reimbursement: Payer coverage expanding as clinical data on safety and efficacy increase.
- Guidelines: Updated testosterone therapy guidelines emphasize personalized treatment, with oral options gaining favor for compliance.
Comparative Analysis: TLANDO vs. Other TRT Modalities
| Parameter |
TLANDO (Oral) |
Injectable Testosterone |
Transdermal Gels/Patches |
Pellet Implants |
| Approval Year |
2019 |
1960s |
1980s |
2000s |
| Dosing Frequency |
Daily |
Every 2–4 weeks |
Daily or weekly |
Every 3–6 months |
| Bioavailability |
Moderate |
High |
Variable |
High |
| Patient Preference |
High |
Moderate |
High |
Moderate |
| Safety Profile |
Favorable (long-term data ongoing) |
Well-established |
Concerns over skin irritation |
Good, but invasive |
FAQs
Q1: What are the key advantages of TLANDO over traditional TRT options?
A1: TLANDO offers an oral, non-invasive administration route, which enhances patient compliance, reduces discomfort associated with injections or skin application, and simplifies therapy management.
Q2: Are there any significant safety concerns with TLANDO?
A2: Long-term safety data are still accumulating, but Phase 3 trials indicate a tolerable safety profile similar to other TRT modalities. Cardiovascular risks common to TRT require continued surveillance.
Q3: How does TLANDO’s market penetration compare to injectable testosterone?
A3: TLANDO’s market share remains smaller (~8% in 2022), but it shows strong growth potential driven by patient preference for oral therapy and convenience.
Q4: What regions are most promising for TLANDO expansion?
A4: North America and Europe are mature markets, but Asia-Pacific, especially Japan and Australia, offer significant growth opportunities pending regulatory approval.
Q5: What future clinical developments could impact TLANDO’s market position?
A5: Long-term safety studies, broader indications, and head-to-head trials against other TRT modalities could bolster confidence and expand usage.
Key Takeaways
- Market Opportunity: The global TRT market is expanding at a CAGR of approximately 7.4%, with oral TRT expected to grow faster (8.2%). TLANDO is positioned as a leading oral option with potential to capture significant market share.
- Regulatory Outlook: Continued approvals and favorable policy shifts are likely, especially in developed regions.
- Clinical Data: Ongoing post-marketing studies aim to solidify TLANDO’s safety profile; expansion into broader demographics could drive growth.
- Competitive Strategy: Emphasizing convenience, safety, and efficacy can differentiate TLANDO amid a crowded TRT landscape.
- Long-term Growth: By 2027, TLANDO could account for a substantial segment of the oral TRT market, supported by increased diagnosis and evolving treatment preferences.
References
- U.S. Food and Drug Administration (2019). FDA approves first oral testosterone medication for hypogonadism.
- ClinicalTrials.gov. (2023). Ongoing clinical trials for TLANDO.
- MarketWatch. (2022). Global Testosterone Replacement Therapy Market Analysis.
- EMA. (2019). Approval summaries for testosterone undelcanoate.
- IQVIA. (2022). Global TRT Market Data.
